Press Announcements > FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients

Press Announcements > FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients





FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients

First drug approved to treat MS in ages 10 and older

The U.S. Food and Drug Administration today approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents age 10 years and older. This is the first FDA approval of a drug to treat MS in pediatric patients. Continue reading.